Fritextsökning
Artiklar per år
Innehållstyper
-
Pengar och support på önskelistan
I senaste Scanbaltrapporten identifierar organisationen fem huvudområden för att förbättra förutsättningarna inom life scienceindustrin i länderna kringa Baltikum. -Självklart siktar vi högt, säger Scanbalts generaldirektör Peter Frank.
-
Här blir innovationer business
Som en del i regeringens strategi för entreprenörskap startas två spetsutbildningar inom entreprenörskap och innovation. Utbildningarna hamnar i Göteborg och i Lund.
-
The winner of the race
She learned how to work hard at an early age and her devotion has certainly paid off. Whether it is field running or running a company, the key to success is focus according to Yvonne Mårtensson.
-
With their hands on the legal levers
It is wonderful news for the Scandinavian scientific community. At the end of May it stood clear that Lund will host to the European Spallation Source.
-
Nya blodtrycksgener identifierade
Åtta hittills okända gener som påverkar blodtrycket har kartlagts i en stor internationell studie.
-
De är bäst på patent
En internationell undersökning placerar Awapatent som nummer ett bland Sveriges patentbyråer.
-
Absorber säljer till USA
Två ledande amerikanska transplantationskliniker köper bolagets antikroppstest.
-
Instrument för skräddarsydd behandling snart här
En apparat stor som en mobiltelefon kan komma att revolutionera förskrivningen av läkemedel.
-
Major changes to the Q-Med board
The nomination committee wants to replace half of the existing board, including the current Chairman. An Extraordinary General Meeting will take place on February 4.
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
Teams up with leading dermatologist
Tripep has signed a letter of intent with a major Japanese specialty pharma company to bring their wound healing treatment to a big market.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
First ever study of human stem cell treatment
The FDA says yes to the world's first study in man of a human embryonic stem cell based therapy to treat spinal injury.
-
Grant for development projects in Gothenburg
Seven research projects receive SEK 1 million to promote commercialization of early drug development and medical technology.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
New study of toxins and heart disease
Is there a correlation between exposure to hormone interfering environmental toxins and increased risk of developing cardiovascular disease? A new patient study will try to evaluate this, and one thousand people are to be included.
-
New member to Active board
The Election Committee of Active Biotech proposes a very experienced financial sector executive to join the company board. Five existing members are also to be re-elected at the AGM in May.
-
Researchers goes to the bottom of the brain
Swedish researchers have recently got new and deeper knowledge about the smallest part of the brain, the granule cells.
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Danisco strengthens its IP team
Danisco's division Genencor has appointed a new Vice President of Intellectual Property Strategy and Chief IP Counsel.
-
Biovitrum sells UK part
Biovitrum will soon spin-out a British subsidary
BREAKING